Bicycle Therapeutics has filed a patent for polypeptides that are covalently bound to molecular scaffolds, allowing for the creation of high affinity binders of Nectin-4. The patent also covers drug conjugates comprising these peptides, as well as their use in preventing, suppressing, or treating diseases mediated by Nectin-4. GlobalData’s report on Bicycle Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Bicycle Therapeutics Plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bicycle Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Bicycle Therapeutics's grant share as of September 2023 was 16%. Grant share is based on the ratio of number of grants to total number of patents.

Polypeptides bound to molecular scaffolds for disease treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Bicycle Therapeutics Plc

A recently filed patent (Publication Number: US20230287047A1) describes a method for synthesizing compound BCY8245. The method involves a series of steps, starting with providing a compound of formula 7, followed by providing compounds of formulas 6, 5, 4, 3, 2, and 1. These compounds are then reacted and transformed into the desired compound BCY8245 or its salt using a solid-phase synthesis.

In one embodiment of the method (claim 29), the compound of formula 8 or its salt is reacted with BCY8234 or its salt in the presence of N,N-diisopropylethylamine (DIEA). Another embodiment (claim 30) involves the reaction of the compound of formula 7 or its salt with NHS in the presence of a carbodiimide, specifically 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI).

The saponifying step (claim 32) in the method involves reacting the compound of formula 6 or its salt with LiOH and H2O. The compound of formula 5 or its salt is reacted with MMAE in the presence of N,N-diisopropylethylamine (DIEA) (claim 33). The compound of formula 4 or its salt is reacted with bis(4-nitrophenyl) carbonate in the presence of N,N-diisopropylethylamine (DIEA) (claim 34). The compound of formula 3 or its salt is reacted with (4-aminophenyl)methanol in the presence of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) (claim 35).

The hydrolyzing step (claim 36) in the method is performed under acidic conditions. Overall, the method provides a detailed process for synthesizing compound BCY8245 or its salt, involving a series of reactions and transformations.

In conclusion, the filed patent describes a method for synthesizing compound BCY8245 or its salt. The method involves a stepwise process starting with specific compounds and utilizing various reactions and transformations. The method provides a detailed and specific approach to produce the desired compound.

To know more about GlobalData’s detailed insights on Bicycle Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies